Elisabet de Los Pinos - 21 Jan 2025 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Conor Kilroy, as Attorney-in-Fact
Issuer symbol
AURA
Transactions as of
21 Jan 2025
Net transactions value
-$122,381
Form type
4
Filing time
21 Jan 2025, 21:09:45 UTC
Previous filing
29 Oct 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AURA Common Stock Sale $122,381 -15,955 -5% $7.67 304,692 21 Jan 2025 Direct F1, F2
holding AURA Common Stock 131,412 21 Jan 2025 By EdIP Revocable Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.67 to $7.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Remarks:

President and Chief Executive Officer